Clinical trials - Cancer Research SA

Filter By

AMT-253-01

Phase 1

Open and recruiting

Advanced Solid Tumors – AMT-253 – Anti-MUC18 ADC

First-in-Human, Phase 1 Study of AMT-253, an Anti-MUC18 Antibody-Drug Conjugate, in Patients with Advanced Solid Tumors
Read more: Advanced Solid Tumors – AMT-253 – Anti-MUC18 ADC
PIONERA: CO44657

Phase 3

Open and recruiting

Breast Cancer: ER+ Her2- after Adjuvant Endocrine failure

A Phase III, Randomized, Open-Label Study Evaluating Efficacy And Safety Of Giredestrant Compared With Fulvestrant, Both Combined With A CDK4/6 Inhibitor, In Patients With Estrogen Receptor-Positive, Her2-Negative Advanced Breast Cancer With Resistance To Prior Adjuvant Endocrine Therapy
Read more: Breast Cancer: ER+ Her2- after Adjuvant Endocrine failure
ZN-C3-005

Phase 2

Open and recruiting

Ovarian Cancer – ZN‑C3 – Platinum refractory Cancer

A Phase 2 Open-Label, Multicenter Study to Evaluate Efficacy and Safety of ZN‑c3 in Subjects with High-Grade Serous Ovarian, Fallopian Tube, or Primary Peritoneal Cancer
Read more: Ovarian Cancer – ZN‑C3 – Platinum refractory Cancer
DF6215-001

Phase 1, Phase 1a, Phase 1b

Open and recruiting

Advanced Solid Tumours – DF6215

A Phase 1/1b, first-in-human, multi-part, open-label study to investigate the safety, tolerability, pharmacokinetics, biological and clinical activity of DF6215 in patients with Advanced (unresectable, recurrent, or metastatic) Solid Tumors
Read more: Advanced Solid Tumours – DF6215
VS-6766-301

Phase 3

Open and recruiting

Ovarian cancer – Recurrent Low-Grade Serous Ovarian Cancer

A Phase 3, Randomized, Open-Label Study of Combination Therapy with Avutometinib plus Defactinib Versus Investigator’s Choice of Treatment in Patients with Recurrent Low-Grade Serous Ovarian Cancer (LGSOC)
Read more: Ovarian cancer – Recurrent Low-Grade Serous Ovarian Cancer
RAD204

Phase 1, Phase 1a, Phase 1b

Open and recruiting

NSCLC – Theranostics – 177Lu-RAD204

Phase 0/1 Study of the Safety and Tolerability of 177Lu-RAD204, a Lutetium -177 Radiolabelled Single Domain Antibody Against Programmed Cell Death-Ligand 1 in Patients with Metastatic Non-small Cell Lung Cancer
Read more: NSCLC – Theranostics – 177Lu-RAD204
LOXO-RAS-20001

Phase 1, Phase 1a, Phase 1b

Open and recruiting

Solid Tumours – LY3537982 – KRAS G12C-Mutant cancers

LOXO-KRAS: A Phase 1a/1b Study of LY3537982 in Patients with KRAS G12C-Mutant Advanced Solid Tumors
Read more: Solid Tumours – LY3537982 – KRAS G12C-Mutant cancers
LOXO-FRA-24001

Phase 1, Phase 1a, Phase 1b

Open and recruiting

Ovarian cancer – LY4170156 – ADC Targeting Folate Receptor

A First-in-Human, Phase 1a/1b Trial to Assess the Safety, Tolerability and Preliminary Efficacy of LY4170156, an Antibody-Drug Conjugate Targeting Folate Receptor a -Expressing Tumor Cells, in Participants with Selected Advanced Solid Tumors
Read more: Ovarian cancer – LY4170156 – ADC Targeting Folate Receptor
BNT113-01 AHEAD-MERIT

Phase 2

Open and recruiting

Head and Neck SCC – 1st line – HPV16+ expressing PDL1

An open-label Phase II randomized trial of BNT113 in combination with pembrolizumab versus pembrolizumab monotherapy as a first line therapy in patients with unresectable recurrent, or metastatic Head and Neck Squamous Cell Carcinoma (HNSCC) which is positive for human papilloma virus 16 (HPV16+) and expresses PD-L1
Read more: Head and Neck SCC – 1st line – HPV16+ expressing PDL1